SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study [Yahoo! Finance]
RadNet, Inc. (RDNT)
Last radnet, inc. earnings: 3/12 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
radnet.com/about-radnet/investor-relations
Company Research
Source: 18F
A second trial focused on PDAC, FAPI-PRO, launched December 2025 DULLES, Va. Dec. 29, 2025 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in one of its two Phase 3 clinical trials evaluating [ F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein (FAP), as a novel diagnostic for patients with GI cancers. "We are proud of this milestone in the continuing clinical development of FAPI," said Patrick Phelps, President and CEO, SOFIE Biosciences. "FAPI provides a different way to image and identify disease, by targeting cancer-associated fibroblasts in the tumor microenvironment. Dosing the first patient with [ F]FAPI-74 brings us one step closer to addressing vital areas of unmet need in gastric and esophageal cancers and realizing the promise of FAPI PET in precision medicine." "FAPI-74 is an exciting new advanced PET tracer" said
Show less
Read more
Impact Snapshot
Event Time:
RDNT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDNT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDNT alerts
High impacting RadNet, Inc. news events
Weekly update
A roundup of the hottest topics
RDNT
News
- RadNet (NASDAQ:RDNT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- 3 Reasons RDNT is Risky and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- RadNet (RDNT) Valuation Check After Short-Seller Allegations and Supportive Analyst Rebuttal [Yahoo! Finance]Yahoo! Finance
- Why Is RadNet (RDNT) Stock Rocketing Higher Today [Yahoo! Finance]Yahoo! Finance
- RadNet, Inc. (RDNT): A Bear Case Theory [Yahoo! Finance]Yahoo! Finance
RDNT
Earnings
- 11/9/25 - Miss
RDNT
Sec Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 12/9/25 - Form 4
- RDNT's page on the SEC website